A blood score linked to how glioma goes over time
Original title: Prognostic value of the systemic inflammation response index (SIRI) in glioma: A meta-analysis.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This looks across many earlier studies rather than running a new one.
This is a summary of past studies, not something a patient can get.
The short version
A score from a routine blood test may hint at how a glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary will behave.
What was studied. Researchers pooled eight past studies that together included 1778 people with glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary. They looked at a blood score called SIRI, which reflects signs of inflammation in the body.
What they found. People with a higher SIRI score tended to live for a shorter time. They also tended to have less time before the tumor grew again. In the group of European patients, the link to how long people lived was not clear.
What this means, and what it doesn't
What it could mean: This blood score may give doctors one more clue about risk. Over time it could help guide how closely someone is watched. It does not change anyone's treatment today.
What it doesn't mean: This is not a treatment, and it is not a cure. The studies looked back at old records, so they cannot prove the score causes a worse outcome. There is no agreed number for what counts as a high score yet. The authors say more studies in different groups of people are needed. Some of the published results may also give a slanted picture.
Source: PubMed, November 2, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.